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Case Report: Treatment of Schistosomiasis in a Patient Allergic to Praziquantel:
A Desensitization and Treatment Protocol
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Abstract. Praziquantel is the mainstay of treatment of Schistosomiasis, which affects at least 262 million people
worldwide. It is also used in the treatment of other trematode as well as cestode infections, with few safe and effective
alternatives. It is generally well tolerated and allergic reactions are rare. In this report, we present a case of schistoso-
miasis with a history of a hypersensitivity reaction to praziquantel. Skin-prick and intradermal testing were performed,
followed by treatment through rapid desensitization. This protocol may be of value to those patients requiring
praziquantel treatment with a history of IgE-mediated allergy to the drug.
INTRODUCTION
Schistosomiasis, also known as bilharzia, is an infectious dis-
ease caused by trematode parasites of the genus Schistosoma.1
Three species account for the majority of human infection—
Schistosoma mansoni, Schistosoma haematobium, and
Schistosoma japonicum. Infection occurs through contact
with freshwater containing cercariae, the larval form released
from snails, the intermediate host. Cercariae penetrate
human skin, become schistosomulae in tissue and migrate
through several tissues and stages to become adult worms,
which take their final residence in the mesenteric veins
(S. mansoni) or in the pelvic venous plexus and veins around
the bladder (S. haematobium). Disease caused by this parasite
results from the immunologic reactions to egg-derived antigens
produced by adult worms in addition to the mechanical effects
of eggs trapped in blood vessel walls.2 The chronic effects, which
can be severe and debilitating, include hepatosplenomegaly,
periportal fibrosis and portal hypertension, and urogenital
inflammation and fibrosis.3 According to the World Health
Organization (WHO), at least 262 million people worldwide
required preventive therapy for schistosomiasis in 2013 (WHO
2015), and more than 700 million people live in endemic areas
(WHO 2014).
Praziquantel, a pyrazino-isoquinoline derivative, is currently
the treatment of choice for schistosomiasis.4,5 It was devel-
oped in 1975 after the discovery of its antihelminthic proper-
ties by Merck and Bayer in 1972.4 It acts against the adult
worms (poor activity against immature schistosome larvae) and
is given in a standard dose of 40 mg/kg for S. haematobium
and S. mansoni and 60 mg/kg for S. japonicum.
There are currently few alternatives to praziquantel. Anti-
monial compounds and metrifonate were previously used
but are now obsolete due to their excessive toxicity. Oxamni-
quine is the only other drug available for treating schistoso-
miasis.6 It is effective against S. mansoni, but has no effect
on S. haematobium. Widespread resistance has occurred, and
it is now only used on a large scale in Brazil. More recently,
research has demonstrated the potential use of artemisinin
derivatives, which only act on the immature larval forms of
developing schistosomes.7 Its use would therefore be limited
to combination therapy with praziquantel in areas of contin-
uous exposure. Further research is needed on dosing, formu-
lation, and drug interactions as well as, more importantly,
the impact in malaria-endemic regions on the development
of resistance before it is adopted for widespread use.
Praziquantel also successfully treats other trematode,
including Fasciola hepatica, Clonorchis sinensis, and Para-
gonimus westermani, and cestode, including Hymenolepisnana,
Diphyllobothrium latum, Echinococcus granulosus, and Taenia
species, infections. It is generally well tolerated (common
transient side effects include headache, dizziness, sleepiness,
abdominal pain, and diarrhea), highly effective, and safe.
Allergic reactions including hypersensitivity reactions and ana-
phylaxis are exceedingly rare and there have only been five
published reports describing hypersensitivity reactions.8–12 In
a Cochrane review of drug treatment of urinary schistosomia-
sis, 30 randomized–controlled trials enrolling 8,165 partici-
pants were included in the analysis. There were no reported
hypersensitivity or anaphylactic reactions to praziquantel in
those studies where data on adverse effects were available.13
In this report, we present a case of allergy to praziquantel
with subsequent successful desensitization and treatment of
schistosomiasis. This case demonstrates the potential utility
of our desensitization protocol for patients who develop an
allergic response to this drug.
CASE REPORT
In August 2012, a 31-year-old white female, normally resi-
dent in the United Kingdom (UK), was referred to the Hospi-
tal for Tropical Diseases, London, for post-tropical screening
having recently returned from Malawi. She had a history of
frequent travel to Africa since her partner was from a village
on the shores of Lake Malawi and had significant freshwater
exposure. She was asymptomatic and had no significant past
medical history. Schistosomiasis enzyme-linked immunosor-
bent assay, microscopy of terminal urine, and stool microscopy
for ova, cysts, and parasites were negative. A full blood count
and differential were normal.
Of note was that she had self-treated with praziquantel
acquired in Malawi in October 2011. She developed pruritic
hands and feet with the first dose, lasting an hour, although tol-
erated the second dose taken several hours later. She repeated
the treatment in January 2012. She took a single dose on this
occasion. Within 1 hour, she developed a generalized migratory
urticaria lasting approximately 1 hour with no other associated
symptoms and no syncopal symptoms or angioedema.
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She had further screening tests in February 2014 having
returned to Lake Malawi in the intervening years. At this
stage, her schistosomiasis serology was positive at level two
(0.494, cutoff 0.260) with all other tests remaining negative.
Since she was due to return again to Lake Malawi, treatment
was deferred until 3 months after her return in November
2014. On return, her serology had risen to positivity at level 4
(0.714), consistent with further freshwater exposure.
This patient was reviewed in the Drug Allergy Unit at Uni-
versity College London Hospital. She underwent standard
allergy assessment involving skin prick (50 mg/mL) and intrader-
mal (1:1,000, 0.05 mg/mL) testing with praziquantel. She tested
negative to both. Despite the negative skin test results, there
was a clear IgE-mediated history of praziquantel allergy and so
the patient was considered suitable for rapid desensitization.
She was premedicated with 200 mg of intravenous hydro-
cortisone 1 hour prior to the procedure. She then underwent
a 12-step rapid desensitization protocol, reaching a cumula-
tive dose of 2,800 mg in 330 minutes. Emergency medication
including adrenaline, antihistamines, hydrocortisone, bron-
chodilators, and oxygen was available. At step 10, a cumula-
tive dose of 1,000 mg, she complained of pruritic earlobes.
No treatment was administered and she recovered within
30 minutes. At step 11, a cumulative dose of 1,800 mg, she
complained of pruritic arms. There was no evidence of a skin
rash or angioedema and again no rescue treatment was
administered. Following complete resolution of the pruritus
30 minutes later, she received her final dose of 1,000 mg
praziquantel. This was well tolerated, except for mild ery-
thema of the toes and mild urticaria of the toes, dorsum of
the feet, anterior thighs, and knees. She was then treated
with oral cetirizine 20 mg. Her urticaria resolved within
30 minutes and the patient was discharged home 1 hour fol-
lowing the completion of the protocol.
DISCUSSION
This report describes the desensitization protocol to
praziquantel in a patient who required treatment of schisto-
somiasis. The diagnosis of drug allergy is based on the
patient’s medical history and, if possible, the results of diag-
nostic (skin or challenge) tests.14
Although her initial immediate hypersensitivity reac-
tion was to praziquantel sourced in Malawi, the symptoms
were reproduced with praziquantel sourced in the United
Kingdom, albeit at a diminished level, during the desensiti-
zation procedure. A challenge test to confirm the diagnosis
was not performed in this case due to the strong history of
two previous reactions.
Treatment with praziquantel is recognized to increase spe-
cific IgE and Th2 responses as a result of the release of anti-
genic proteins from dying eggs and worms.15 However, the
timing of this response, which may in itself result in a hyper-
sensitivity reaction in the setting of a heavy burden of infec-
tion, would be much later than immediate post-ingestion of
the drug as in this case.
Skin testing to praziquantel is neither standardized nor
validated. The predictive value of the test is therefore vari-
able. Lower dilutions of the drug were not used in this case
for further intradermal testing as the large drug particles
would likely give an irritant reaction indistinguishable from a
true positive reaction.
In this case, it was deemed necessary to treat the patient
for her current infection with praziquantel, which involved a
desensitization process as no suitable alternative drug treat-
ment is available. Desensitization aims at altering the immune
response to the drug and results in temporary tolerance,
allowing the patient to receive the medication. Praziquantel,
whose exact mechanism of action against trematodes and
cestodes remains unclear, is rapidly absorbed through the
gastrointestinal tract (up to 80% of the orally administered
dose) and reaches its maximum plasma concentration within
1–2 hours.16 In view of the short half-life of the drug and its
rapid elimination, we designed a rapid drug desensitization
protocol (Table 1). Premedication for desensitization can be
achieved with steroids, antihistamines, H2-receptor antagonists,
and leukotriene receptor antagonists such as montelukast. They
are used to ameliorate minor IgE-mediated symptoms some
patients experience during the course of desensitization. In
this case, hydrocortisone was the steroid used. It is worth
noting that in sensitized patients, administration of premedi-
cation followed by full therapeutic dose of a drug may not
prevent anaphylaxis.17
Desensitization involves the reintroduction of small, but
incrementally increasing, amounts of the drug at fixed time
intervals. Rapid drug desensitization (RDD) protocols are
remarkably safe and allow for administration of the full dose
of first-line therapy in as many as 99.9% of patients.18 The
mechanism of RDD is not fully understood. However, the
biochemical mechanism by which RDD induces specific mast
cell tolerance is likely to be associated with the molecular
stabilization of membrane-bound IgE receptors.19
There are only two previous published methods of
praziquantel desensitization. In one report, the procedure
involved increasing doses in a total of seven increments at
90-minute intervals.8 In this case, 30 minutes after the sixth
dose, half of the total maximum dose, the patient developed
an urticarial rash that was subsequently managed with 250 mg
intravenous hydrocortisone and an anti-histamine. Three fur-
ther days of praziquantel treatment were given, for P. westermani
infection, with no adverse effects. The second report involved
premedication with hydroxyzine (10 mg every 6 hours), dexa-
methasone (4 mg IV every 6 hours), and prednisone (15 mg
every 8 hours) 6 hours before administering praziquantel in
13 divided doses at 15-minute intervals.11 Hydroxyzine and
praziquantel were continued for a total of 24 days and predni-
sone for an additional 2 weeks. The regimen used in this case
was for the treatment of neurocysticercosis, hence the high
corticosteroid use and lengthy treatment course. It would be
TABLE 1
Praziquantel desensitization protocol table
Sequence/time (minutes) Dose (mg) Cumulative (mg)
1/30 0.5 0.5
2/60 1.5 2
3/90 5 7
4/120 13 20
5/150 30 50
7/180 60 110
8/210 120 230
9/240 270 500
10/270 500 1,000
11/300 800 1,800
12/330 1,000 2,800
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difficult to justify using these doses in the case of preventive
therapy for schistosomiasis and it was unclear in this report
whether true desensitization was achieved. In comparison to
these two methods, ours minimized the development of a Type
I hypersensitivity reaction without the excessive use of cortico-
steroids. To date, the patient has not required re-treatment
with praziquantel, but is likely to require further desensitiza-
tion should the need arise.
Allergic reactions to praziquantel seem to be an emerging
problem. It is a highly efficacious drug in the treatment of
trematode and cestode infections where alternatives are lack-
ing. Our protocol for desensitization is a method that could
be used for those patients who report hypersensitivity.
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